Radiogenomic biomarkers for immunotherapy in glioblastoma: A systematic review of magnetic resonance imaging studies
Clicks: 74
ID: 281580
2024
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
21.9
/100
74 views
21 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #475 of 803 articles by views in arXiv
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 803 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Immunotherapy is an effective precision medicine treatment for several
cancers. Imaging signatures of the underlying genome (radiogenomics) in
glioblastoma patients may serve as preoperative biomarkers of the tumor-host
immune apparatus. Validated biomarkers would have the potential to stratify
patients during immunotherapy clinical trials, and if trials are beneficial,
facilitate personalized neo-adjuvant treatment. The increased use of whole
genome sequencing data, and the advances in bioinformatics and machine learning
make such developments plausible. We performed a systematic review to determine
the extent of development and validation of immune-related radiogenomic
biomarkers for glioblastoma. A systematic review was performed following PRISMA
guidelines using the PubMed, Medline, and Embase databases. Qualitative
analysis was performed by incorporating the QUADAS 2 tool and CLAIM checklist.
PROSPERO registered CRD42022340968. Extracted data were insufficiently
homogenous to perform a meta-analysis. Results Nine studies, all retrospective,
were included. Biomarkers extracted from magnetic resonance imaging volumes of
interest included apparent diffusion coefficient values, relative cerebral
blood volume values, and image-derived features. These biomarkers correlated
with genomic markers from tumor cells or immune cells or with patient survival.
The majority of studies had a high risk of bias and applicability concerns
regarding the index test performed. Radiogenomic immune biomarkers have the
potential to provide early treatment options to patients with glioblastoma.
Targeted immunotherapy, stratified by these biomarkers, has the potential to
allow individualized neo-adjuvant precision treatment options in clinical
trials. However, there are no prospective studies validating these biomarkers,
and interpretation is limited due to study bias with little evidence of
generalizability.
| Reference Key |
booth2024radiogenomic
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Prajwal Ghimire; Ben Kinnersley; Golestan Karami; Prabhu Arumugam; Richard Houlston; Keyoumars Ashkan; Marc Modat; Thomas C Booth |
| Journal | arXiv |
| Year | 2024 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.